Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
Venema CM, Mammatas LH, Schröder CP, van Kruchten M, Apollonio G, Glaudemans AWJM, Bongaerts AHH, Hoekstra OS, Verheul HMW, Boven E, van der Vegt B, de Vries EFJ, de Vries EGE, Boellaard R, Menke van der Houven van Oordt CW, Hospers GAP. Venema CM, et al. Among authors: van kruchten m, van der vegt b. J Nucl Med. 2017 Dec;58(12):1906-1912. doi: 10.2967/jnumed.117.193649. Epub 2017 Sep 14. J Nucl Med. 2017. PMID: 28912144 Free article. Clinical Trial.
Association of Initial and Longitudinal Changes in C-reactive Protein With the Risk of Cardiovascular Disease, Cancer, and Mortality.
Suthahar N, Wang D, Aboumsallem JP, Shi C, de Wit S, Liu EE, Lau ES, Bakker SJL, Gansevoort RT, van der Vegt B, Jovani M, Kreger BE, Lee Splansky G, Benjamin EJ, Vasan RS, Larson MG, Levy D, Ho JE, de Boer RA. Suthahar N, et al. Among authors: van der vegt b. Mayo Clin Proc. 2023 Apr;98(4):549-558. doi: 10.1016/j.mayocp.2022.10.013. Mayo Clin Proc. 2023. PMID: 37019514 Free PMC article.
Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.
Hartog H, Horlings HM, van der Vegt B, Kreike B, Ajouaou A, van de Vijver MJ, Marike Boezen H, de Bock GH, van der Graaf WT, Wesseling J. Hartog H, et al. Among authors: van der graaf wt, van de vijver mj, van der vegt b. Breast Cancer Res Treat. 2011 Oct;129(3):725-36. doi: 10.1007/s10549-010-1256-6. Epub 2010 Nov 24. Breast Cancer Res Treat. 2011. PMID: 21107683
Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets.
Nienhuis HH, Gaykema SB, Timmer-Bosscha H, Jalving M, Brouwers AH, Lub-de Hooge MN, van der Vegt B, Overmoyer B, de Vries EG, Schröder CP. Nienhuis HH, et al. Among authors: van der vegt b. Pharmacol Ther. 2015 Mar;147:63-79. doi: 10.1016/j.pharmthera.2014.11.004. Epub 2014 Nov 6. Pharmacol Ther. 2015. PMID: 25444756 Review.
Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer.
de Boer E, Crane LM, van Oosten M, van der Vegt B, van der Sluis T, Kooijman P, Low PS, van der Zee AG, Arts HJ, van Dam GM, Bart J. de Boer E, et al. Among authors: van oosten m, van der sluis t, van dam gm, van der vegt b, van der zee ag. PLoS One. 2015 Aug 6;10(8):e0135012. doi: 10.1371/journal.pone.0135012. eCollection 2015. PLoS One. 2015. PMID: 26248049 Free PMC article.
Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer.
Koch M, de Jong JS, Glatz J, Symvoulidis P, Lamberts LE, Adams AL, Kranendonk ME, Terwisscha van Scheltinga AG, Aichler M, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WP, Van der Wall E, Garcia-Allende PB, van Diest PJ, de Vries EG, Walch A, van Dam GM, Ntziachristos V. Koch M, et al. Among authors: van der wall e, van diest pj, van dam gm, van der vegt b. Cancer Res. 2017 Feb 1;77(3):623-631. doi: 10.1158/0008-5472.CAN-16-1773. Epub 2016 Nov 22. Cancer Res. 2017. PMID: 27879266
Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.
Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, Terwisscha van Scheltinga AGT, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WPTM, Van der Wall E, van Diest PJ, de Vries EGE, Ntziachristos V, van Dam GM. Lamberts LE, et al. Among authors: van der wall e, van diest pj, van dam gm, van der vegt b. Clin Cancer Res. 2017 Jun 1;23(11):2730-2741. doi: 10.1158/1078-0432.CCR-16-0437. Epub 2016 Nov 9. Clin Cancer Res. 2017. PMID: 28119364 Clinical Trial.
Micro-computed tomography (micro-CT) for intraoperative surgical margin assessment of breast cancer: A feasibility study in breast conserving surgery.
Qiu SQ, Dorrius MD, de Jongh SJ, Jansen L, de Vries J, Schröder CP, Zhang GJ, de Vries EGE, van der Vegt B, van Dam GM. Qiu SQ, et al. Among authors: van dam gm, van der vegt b. Eur J Surg Oncol. 2018 Nov;44(11):1708-1713. doi: 10.1016/j.ejso.2018.06.022. Epub 2018 Jul 3. Eur J Surg Oncol. 2018. PMID: 30005963
89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up.
Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, de Vries EGE, Schröder CP. Bensch F, et al. Among authors: van der vegt b. Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2300-2306. doi: 10.1007/s00259-018-4099-8. Epub 2018 Jul 30. Eur J Nucl Med Mol Imaging. 2018. PMID: 30058029 Free PMC article.
154 results